TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
